Overview
Clinical Benefits
- Exceptional weight loss (up to 24% body weight)
- Appetite suppression via triple receptor activation
- Blood sugar control
- Potential metabolic and cardiovascular benefits
- Increased energy expenditure via glucagon activation
Administration
Subcutaneous injection — abdomen, thigh, or upper arm
Drug class: glp1 gip glucagon triple agonist
Clinical Dosing
Typical dosage
1mg starting, titrate up to 12mg
Starting dose
1mg
Cadence
Once weekly
Full titration schedule
| Phase | Dose |
|---|---|
| Weeks 1-4 | 1mg once weekly |
| Weeks 5-8 | 2mg once weekly |
| Weeks 9-12 | 4mg once weekly |
| Weeks 13-16 | 8mg once weekly |
| Weeks 17+ | 12mg once weekly (maintenance) |
Safety Profile
Side effects
- • Nausea (most common, especially during titration)
- • Diarrhea
- • Vomiting
- • Constipation
- • Decreased appetite
Contraindications
- • Medullary thyroid carcinoma
- • MEN 2 syndrome
- • Pancreatitis history
- • Severe gastrointestinal disease
Do not combine with
Featured in these stacks
Stack 03
Elite DirectThe GOAT
Precision metabolic recomposition
Retatrutide — first-line triple-agonist (GLP-1 + GIP + glucagon) for the most aggressive fat-loss + glycemic-control profile.
View stack
Stack 04
Elite DirectExercise Mimetic Stack
Train your mitochondria without leaving the lab
Retatrutide — triple-agonist (GLP-1 + GIP + glucagon) for aggressive body recomposition during the mimetic cycle.
View stack
Frequently asked questions
Retatrutide is most commonly researched for: Exceptional weight loss (up to 24% body weight), Appetite suppression via triple receptor activation, Blood sugar control, Potential metabolic and cardiovascular benefits.
Ready to build a protocol with Retatrutide?
LIA, our clinical reasoning engine, will build a personalized protocol — dosing, cadence, cycling, and safety checks — tailored to your goals and intake.
You’ll be asked to sign in first. Free tier includes the chat preview.
Information on this page is for educational purposes only and is not medical advice. Peptides should only be used under the supervision of a qualified healthcare provider.